Anxiety Sensitivity Treatment for Heroin Users

Anxiety Clinical Trial

— ASTH-HR  

Official title:

Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01196312
• Other study ID #: DA023384
• Status: Completed
• Phase: N/A
• Start date: October 2009
• Est. completion date: September 2011

Study information

• Verified date: May 2023
• Source: University of Maryland, College Park
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anxiety Sensitivity Treatment for Heroin Users is a development project targeting mild and above levels of anxiety sensitivity that will involve the testing of a specialized protocol for improving treatment retention and outcomes for heroin dependent individuals in a residential substance use treatment. ASTH-HR will integrate established treatment modules such as Healthy Relationships, along with interoceptive exposure, affect management, and psycho-education exercises developed for anxiety prevention and treatment programs with standard substance use treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: September 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• exhibit a score of 21 on a self-report measure of anxiety sensitivity

• be in 28 days of residential substance use treatment.

• meet criteria for current opioid dependence as determined by SCID interview administered at intake.

Exclusion Criteria:

• evidence of limited mental competency

• the inability to give informed, voluntary, written consent to participate

• current psychosis

• current bipolar disorder.

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders

Intervention

Behavioral:
• Anxiety sensitivity therapy
ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).

Locations

Country	Name	City	State
United States	Salvation Army Harbor Light Treatment Facilitiy	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, College Park

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anxiety Sensitivity Index-3		24 weeks
Secondary	Timeline Follow Back 90 days		24 weeks